Air Maestro, a leading SaaS provider of critical safety management systems, flight operations, and training solutions, has been supporting aviation operators since 2005. Its comprehensive Operational and Safety Management System is trusted by the globe’s most dynamic aviation operators. Spidertracks empowers the aviation industry with real-time aircraft management and proactive safety decisions. Committed to enhancing aviation safety, Spidertracks assists thousands of aviators worldwide to ensure their teams return home safely every day. Air Maestro and Spidertracks are uniting their already complementary efforts towards a common goal and addressing critical, unserved needs in the global aviation industry. They will achieve this by delivering a unified software platform that leverages the strengths of each company’s offerings, and expand the suite of services available to customers that will deliver unparalleled value to the market. | Vellox Group is a fully unified software platform integrating the capabilities of five historically independent, market-leading businesses: Spidertracks, Air Maestro, Flight Vector, ADSoftware and Complete Flight. Our industry-leading platform provides the most comprehensive suite of solutions, equipping decision-makers with the insights, innovation, and agility needed to adapt to evolving market demands and maintain excellence at every stage of operations. Leading air—and increasingly ground—operators trust Vellox Group to ensure efficiency, compliance, safety, and operational excellence. Powered by a global team of industry experts and cutting-edge AI, Vellox Group’s integrated operations, fleet, dispatch, maintenance and safety systems provide unmatched effectiveness and control.
Seonixbio
SSeonixBio SightScore is an advanced genetic test that assesses an individual’s inherited risk of developing glaucoma and age-related macular degeneration (AMD). By analysing key genetic markers, SightScore helps clinicians identify high-risk patients earlier, enabling personalised monitoring, earlier intervention, and more proactive management to help preserve long-term vision outcomes.
Myriota
Global leaders in low-cost, low-power, secure direct-to-orbit satellite connectivity for the Internet of Things.
Government of South Australia
South Australia South Australia is characterised by deep clinical research, manufacturing and an end-to-end clinical trial value chain supported by world-class infrastructure and digital capabilities. South Australia: Connected Innovation South Australia is characterised by deep clinical research, manufacturing and an end-to-end clinical trial value chain supported by world-class infrastructure and digital capabilities. It is a superbly collaborative and connected ecosystem for drug development, advanced manufacturing and health innovation. End-to-end clinical trial capabilities Australia’s unique regulatory framework means rapid start-up time without compromises. South Australia’s complete ecosystem is your most strategic entry point for exploring the whole Australian clinical trials sector, clustering end to end advice and expertise which provides the most efficient pathway to your clinical trial conduct. The state’s major hospitals each have world-class infrastructure with dedicated clinical trial units allowing access to dedicated investigators leading clinical research. South Australia is an ideal location for both healthy individuals and patients, including specialised patient populations. Fast and trusted for global markets (including FDA, EMA, TGA), working in South Australia will help you start your clinical trials in as little as six weeks. Data-driven precision health innovation Adelaide is home to world-leading artificial intelligence and data analytics capabilities, supported by unique clinical infrastructure and longitudinal datasets and biospecimen for cutting-edge clinical research and drug development. The Australian Institute for Machine Learning (AIML) has top globally ranked capability in artificial intelligence, machine learning, computer vision research and deep learning. AIML works with leading global companies including Roche, GSK and Medtronic to push the frontier of precision health. Manufacturing capability Australia’s commercial drug manufacturing pedigree was forged in South Australia and features many of its leading academic manufacturing resources and long-established commercial operations. Our contract development manufacturing organisations (CDMOs) support process development through to the cGMP clinical and commercial scale manufacturing to global regulations, with capability and breadth across small and large molecules. Adelaide is home to global operations for pharma and nutraceutical therapeutics, generics and supplement manufacturers. Drug development and biotech South Australia is a centre for drug research and new biotech companies. Key opinion leaders focus on drug development across a wide range of specialisations including immunology, infectious diseases, neuroscience and endocrinology. Oncology is a major focus, including precision health, Car-T technology, computational systems, epigenetics, single cell and spatial technologies, gene regulation, molecular signalling, translational oncology and cancer genomics. Connected innovation precincts Adelaide’s flagship precincts bring together worldclass researchers, companies, government, academia, infrastructure, investment, teaching and clinical care to create unique opportunities for innovation that underpin the state’s leadership and strengths in health and medical sectors. These include Adelaide BioMed City, Tonsley and Lot Fourteen Innovation Districts, ensuring health and life science research, manufacturing and clinical care are embedded with technology innovation. This makes Adelaide and South Australia the perfect location to collaborate, innovate, and trial new products, ready for global commercialisation. The Department of State Development facilitate: • Companies contemplating expansion to Australia and/or the Asia Pacific region via Australia. • Companies and investors looking for investment opportunities. • Companies who are interested in connecting with South Australian companies for services, products and/or collaboration.
EOLOGIX-PING
At EOLOGIX-PING, our commitment to revolutionizing wind energy is evident through our continuous blade health monitoring solutions. Dedicated to ensuring the optimal performance of wind turbines, our advanced sensor systems, driven by cutting-edge technology, detect issues such as icing, blade damage, and lightning strikes. This empowers wind turbine operators with the data they need for informed decisions, ensuring their turbines operate at their best. Whether our customers are setting up new turbines or upgrading existing ones, our solutions seamlessly integrate, maximizing turbine performance and providing operators with peace of mind. As we actively contribute to the global shift towards clean energy, our mission remains clear: Together, we keep wind turbines turning with blade health monitoring. Looking forward, our vision is to unlock the full potential of every wind turbine, continuously innovating and embracing technological advancements while remaining steadfast in our commitment to sustainability. At EOLOGIX-PING, we envision a future where we are recognized not just for technology but as a service company revolutionizing wind energy. | At EOLOGIX-PING, we dedicate ourselves to optimizing wind turbine performance. Our advanced sensor systems detect issues like icing, blade damage, and lightning strikes, providing crucial data for informed decisions. Our solutions seamlessly integrate, ensuring peace of mind and maximizing turbine efficiency.
Colbotic Automation
At Colbotic Automation, our vision is to apply welding automation to components with small to medium batch sizes. We specialize in using collaborative welding robots and developing custom software to simplify robot programming. Our unique capabilities include advanced sensing for improved weld quality and software that enables dual workstation functionality for enhanced productivity.
Agilex Biolabs
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical and GLP toxicology laboratory, has been delivering bioanalytical services for non-clinical studies and clinical trials for over 28 years. Agilex boasts world-class facilities equipped with cutting-edge equipment, including 17 Sciex API LC-MS/MS mass spectrometers to measure small molecule drugs, including novel chemical entities, nucleotides, enantiomers, peptides. Their immunoassay and immunobiology laboratories feature state-of-the-art equipment for large molecule bioanalysis, such as Gyrolab xPlore, MSD Quickplex 120, BD FACSymphony A3 flow cytometers, and BioRad droplet digital quantitative real-time analysers for RNA, siRNA, and miRNA clinical trials, including vaccines and gene therapy trials. Agilex also offers a range of rodent toxicology, including non-GLP and GLP toxicology services and pharmacokinetics studies, to support preclinical through to early/late-phase clinical programs at its custom-built, state-of-the-art GLP facility in Brisbane, Australia. With expertise in all types of molecules, laboratory species, routes of administration, and non-clinical studies, in addition to multiple certifications such as ISO/IEC17025 accreditation and OECD GLP recognition with NATA, Agilex ensures the highest quality standards for seamless end-to-end testing from preclinical to clinical analysis. As a proud member of the Healius network and through its partnership with global laboratory provider SGS, Agilex Biolabs offers a one-stop-shop package to support multi-region drug development from preclinical to late phase, accelerating hundreds of nonclinical and clinical trials for sponsors from the USA, APAC, and Europe.